

Mary Min-chin Lee, M.D., FAAP

Chief Scientific Officer and Enterprise VP, Nemours Health Care
 Physician-in-Chief, Nemours Delaware Valley Operations and
 Nemours Alfred I duPont Hospital for Children
 1600 Rockland
 Wilmington, DE 19803

Education

MD, SUNY-Buffalo School of Medicine, Buffalo, NY	1979-1983
AB, Harvard College, East Asian Languages and Civilizations (Magna cum laude) Cambridge, MA	1975-1979

Postgraduate Training

Research fellow, Pediatric Surgery Developmental Biology Laboratories Massachusetts General Hospital, Boston, MA	1989-1992
Fellow, Pediatric Endocrine and Metabolism, Children's Hospital of Philadelphia University of Pennsylvania Medical School, Philadelphia, PA	1986-1989
Intern and Resident in Pediatrics, Children's Hospital of Buffalo SUNY-Buffalo School of Medicine, Buffalo, NY	1983-1986

Other Educational & Development Programs

Lean Six Sigma Black Belt Certification Center for Innovation and Transformation, UMMHC, Worcester, MA	2016-2017
Fellow, Hedwig van Ameringen Executive Leadership in Academic Medicine (ELAM) Program for Women at Drexel University College of Medicine Philadelphia, Pennsylvania	2014-2015
Mindful Physician Leadership Program, UMass Medical School, Worcester, MA	2014-2015
Teachers of Tomorrow Program, UMass Medical School, Worcester, MA	2012- 2013
AMSPDC Program for New Chairs Atlanta, Georgia	Mar 2013
AAMC Leadership Program for Associate Deans and Department Chairs Babson Executive Conference Center, Wellesley, MA	Sept 2012
AAMC Executive Development Seminar for Interim and Aspiring Leaders AAMC, Washington, DC	May 2012
Fellow, AMSPDC Pediatric Leadership Development Program (one year pediatric department chair development program)	2012-2013
Crucial Confrontations in Medical Practice Management	Feb 2011

University of Massachusetts Medical School, Worcester, MA

Leadership Strategies for Evolving Health Care Executives
Harvard School of Public Health, Brookline, MA Nov 2009

AAMC Mid-Career Women's Faculty Development Seminar, Lansdowne, VA July 2005

Appointments

Chief Scientific Officer and Enterprise VP, Nemours Health Care 2018-present

Physician-in-Chief, Nemours Delaware Valley Operations and Nemours
Alfred I duPont Hospital for Children 2018-present

Professor of Pediatrics 2018-present
Sidney Kimmel Medical College, Jefferson University

The Stoddard Chair of Pediatrics 2015-2018
University of Massachusetts Medical School, Worcester, MA

Chair, Department of Pediatrics 2013-2018
University of Massachusetts Medical School, Worcester, MA

Physician-in-Chief, UMass Memorial Children's Medical Center 2013-2-18
UMass Memorial Health Care Center, Worcester, MA

Interim Chair, Department of Pediatrics 2012-9/2013
University of Massachusetts Medical School, Worcester, MA

Interim Physician-in-Chief, UMass Memorial Children's Medical Center 2012-9/2013
UMass Memorial Health Care Center, Worcester, MA

Co-Director of Clinical & Translational Research, Diabetes Center of Excellence 2011-2018
UMassMemorial Health Care /UMass Medical School, Worcester, MA

Vice-Chair of Academic Affairs, Department of Pediatrics 2009-9/2013
University of Massachusetts Medical School Worcester, MA

Chief, Pediatric Endocrine Division, Department of Pediatrics 2004- 2013
UMass Memorial Health Care/UMass Medical School, Worcester, MA

Professor of Pediatrics & Cell Biology (Tenured, 2004) 2004-2018
University of Massachusetts Medical School, Worcester, MA

Associate Professor of Pediatrics (Tenured, 2003) 2000-2004
Duke University Medical School, Durham, NC

Assistant Professor of Pediatrics 1993-2000
Harvard Medical School, Brookline, MA

Assistant Pediatrician 1993-2000
Massachusetts General Hospital, Boston, MA

Instructor in Pediatrics,
Harvard Medical School, Brookline, MA 1990-1993

Assistant in Pediatrics
Massachusetts General Hospital, Boston, MA 1990-1993

Instructor of Pediatrics
University of Pennsylvania School of Medicine, Philadelphia, PA 1986-1989

Other positions

Medical Director,
Barton Center for Diabetes Education, N. Oxford, MA 2012-2018
2005-2009
Medical Director, Endocrine and Diabetes Teen Clinic
Saints Memorial Hospital, Lowell, MA 1998-2000

Professional Certification

Maintenance of Certification, Pediatric Endocrinology (active),
American Board of Pediatrics 2010-present
Re-certification, Diplomate in Pediatric Endocrinology, American Board of Pediatrics 2013; 2003;
1997
Diplomate in Pediatric Endocrinology
American Board of Pediatrics Sub-Board in Pediatric Endocrinology 1989-1997
Diplomate in Pediatrics, American Board of Pediatrics (lifetime) 1987
Diplomate, National Board of Medical Examiners 1983

Licensure

Pennsylvania 2018-present
Delaware 2018-present
North Carolina Medical License (inactive) 2000-2004
Maine temporary medical license (expired) 1997-1998
Massachusetts Medical License (inactive) 1989-2018
Pennsylvania Medical License (inactive) (active pending) 1986-1990

Honors and Awards

UMMS Chancellor's Award for Advancing Institutional Excellence in Diversity 2018
President, Pediatric Endocrine Society 2017-2018
Vice-President and President Elect, Pediatric Endocrine Society 2016-2017
Chief Resident Education Award 2017
President, American Society of Andrology 2016-2017
Vice-President, American Society of Andrology 2015-2016
Top Pediatricians in America 2012-2017
External Scientific Advisory Board 2010-2015
Breast Cancer & the Environment Research Programs (NIEHS and NIC)
National Advisory Scientific Council 2010-2014
National Institute of Environmental Health Sciences, RTP, NC
Best Doctors of America 2005-2019
American Pediatric Society (member) 2006-present

Castle Connelly Central MA Top Doctors	2013-2018
SubBoard of Pediatric Endocrinology, American Board of Pediatrics (member)	2005-2011
Society for Pediatric Research (member)	1998-present

Professional Memberships and Activities

ELUM (ELAM Alumnae), Drexel University	2015-present
American Academy of Pediatrics	2015- present
Council on Environmental Health and Section on Endocrinology	2015-present
American Board of Pediatrics, Pediatric Endocrine SubBoard	2015-2018
MOC Self Assessment Question Writer	
Association of Medical School Pediatric Department Chairs (AMDSPC)	2013-present
Program Planning Committee (2017-2019)	
New Chairs Committee (2017-2019)	
Worcester District Medical Society	2013-2018
Nominating Committee (2017-2023)	
Women's Caucus (2015-present)	
US News & World Report, America's Best Hospitals	2007-2008
Pediatric Endocrine Working Group	
Pediatric Academic Societies	2006-present
Program Committee (2010-2013)	
Pediatric Academic Societies/Society for Pediatric Research Annual Meeting	
Chair, Ross Clark Annual Highlights Symposium (2011)	
Chair, Obesity Abstract review panel (2010-2013)	
Co-chair, Basic Science Platform presentations (2009-2010)	
Chair, Pediatric Endocrine Abstracts Review Panel (2008-2010)	
Chair, Pediatric Endocrine Awardee Symposium (2007)	
Co-Chair, Plenary symposium on Endocrine Disruptors (2006)	
Moderator, Subspecialty Poster Symposium (1999)	
The Triangle Reproductive Biology Consortium	2000-2004
North Carolina Pediatric Society	2000-2004
The American Society of Andrology	1999-present
Nominating Committee (2016-2019, Chair (2017-2018)	
President (2016-2017)	
Executive Committee (2015-2018)	
Vice President and President-elect (2015-2016)	
Awards Committee (2015-present)	
Constitution and By-Laws Committee (2011-2014)	
Nominating Committee (Chair, 2017-2018; 2008-2011, 2001-2003)	
Andrology Examination Committee (2006-2011)	
Ethics Committee (2006-2008)	
Program Committee	
For 2007 Meeting (2005-2007)	
For 2016 Meeting (2014-2016)	
Executive Council (2003-2006)	
Testis Workshop Program Committee (2001-2003)	
Women in Andrology (2000-present)	
Chair (2006-2007)	
Co-Chair (2005-2006)	
The Society for Pediatric Research	1998-present
Program Committee representative (2010-2013)	
The American Diabetes Association	1994-1996

The Endocrine Society	1992-present
Pediatric Endocrine Society (aka Lawson Wilkins Pediatric Endocrine Society)	1991-present
President (2017-2018)	
President-elect (2016-2017)	
Awards and Nominations Committee (2016-2023, chair, 2018-2019)	
Disorders of Sex Development Advisory Board (2007-2010)	
LWPES-ESPE GnRH consensus workshop (2007)	
Program Committee (2005-2010; Chair, 2009-2010)	
Ad-hoc member (2010-present)	
Membership Committee (1997-2000; Chair, 1999-2000)	
Drug and Therapeutics Committee (1993-1996)	
PES and ESPE: Subcommittee for the Update of the Consensus Guidelines for Care of Children with Disorders of Sex Development (2014-2015)	

Editorial Responsibilities

Spermatogenesis (Editorial Board)	2010-2013
J Andrology (Editorial Board)	2008-2016
J Cellular Physiology (Associate Editor)	2006-present
Endocrinology (Editorial Board)	2005-2008
Manuscript reviewer:	1990-present
<i>New England J Medicine; J Clinical Endocrinology & Metabolism; J Pediatrics; British Medical J; Endocrine Reviews; Endocrinology; Biology of Reproduction; Andrology (formerly J Andrology; Pediatrics; Molecular & Cellular Endocrinology; Pediatrics; J Cellular Physiology; Reproduction; Environmental Health Perspectives; J Pediatric Endocrinology; Spermatogenesis; JAMA; AJDC</i>	

Educational Activities

Teaching Activities

<i>University of Massachusetts Medical School</i>	2004-2017
Lecturer, Medical physiology (125 students)	2010
Lecturer, Students, residents & endo fellows clinical conferences	2004-2017
Clinical supervision & bedside teaching of students and residents	2004-2017
<i>Duke University Medical Center</i>	2000-2004
Mentor for first and third year medical students	
Supervisor, Third year medical student ambulatory continuity program	
Pediatric resident lecture series, Katz teaching rounds, and research conferences	
Pediatric endocrine fellowship: supervision of educational activities and training	
<i>Massachusetts General Hospital/Harvard Medical School</i>	1990-2000
Grand rounds, resident & medical student conferences and didactic lectures	
First year students' pediatric physical diagnosis (Introduction to Clinical Medicine)	
General Pediatric ward attending, teaching rounds	
Pediatric endocrine fellowship: supervision of educational activities and training	

Advising and Supervision

Thuy Lam, ScD in Environmental Health (PhD research committee member) "Dioxin and PCB effects on Pubertal Progression and Sexual Maturity,"	2012-2016
--	-----------

Harvard School of Public Health, Brookline, MA Abigail Fleisch, MD, Ped Endocrine fellow & MPH student (MPH research advisor) "Serum IGF-1 in boys with lead associated growth failure,"	2011-2012
Harvard School of Public Health, Brookline, MA Shwetha Adhikari, M.B.B.S. (research mentor) Department of Pediatrics, UMass Medical School, Worcester, MA	2009-2010
Olivier Humblet, ScD in Environ Health/Epidemiology (PhD research advisor) "Dioxins, PCBs and Pubertal Development among Russian Boys:Lifestage and Genetic Susceptibility," Harvard School of Public Health, Brookline, MA	2005-2010
Olga Hardy, MD, Masters of Clinical Investigation (Chair, MCI thesis committee) "Differential gene expression in metabolically healthy and unhealthy fat" UMass Medical School, Worcester, MA	2008-2010
Xiufeng Wu, MD, PhD, MPH (MPH thesis committee and research mentor) "Environmental exposures and perinatal complications,"UMass Medical School, Worcester, MA	2008-2010
Jane Burns, ScD, Harvard School of Public Health, (postdoc research mentor) "Organochlorines and Pesticide exposure, Nutrition, and Growth" Harvard School of Public Health, Brookline, MA	2007-2015
Benjamin Nwosu, MD (faculty research mentor) "Weight gain and vitamin D in youth on atypical antipsychotics" Department of Pediatrics, UMass Medical School, Worcester, MA	2006-2010
Sofia Alhassan, PhD (faculty mentor on K award) "African dance in mother/daughter dyads, weight gain, and metabolic health" Department of Kinesthesiology, UMass Amherst, Amherst, MA	2010-2015
Ashley Ferullo (medical student advisor) UMass Medical School, Worcester, MA	2006-2010
Xinna Chen, MD, (postdoctoral fellowship research mentor) "Perinatal Leydig cell development in androgen insensitivity" Department of Pediatrics, UMass Medical School, Worcester, MA	2008-2009
Kelby Maher (resident advisor) Department of Pediatrics, UMass Medical School, Worcester, MA	2005-2008
Ramamani Arumugam, Ph.D (postdoctoral research mentor) "MIS signaling in Leydig cells, "Department of Pediatrics, Duke University Medical Center, Durham, NC	2000-2003
Madhusmita Misra, M.D. (pediatric endocrine fellow, clinical research mentor) "Validation of MIS measurement in disorders of gonadal development" Pediatric Endocrine, MGH, Boston, MA	1999-2002
Vijay Sriraman, PhD. (PhD project research mentor) "In vivo effects of MIS on androgen biosynthesis, " Rockefeller University, NY, NY	1999-2002
ChingChing Seah, M.S. (research mentor and MS thesis advisor) "MIS receptor expression and function in Leydig cells" Pediatric Endocrine Division, MGH, Boston, MA	1998-1999
Andrew Lane, M.D. (pediatric endocrine fellow, clinical research mentor) "MIS in children with disorders of sex development" Pediatric Endocrine Division, MGH, Boston, MA	1996-1999
Alexander Trbovich, M.D., Ph.D. (research fellow, research mentor) "Identification of the MIS type 2 receptor" Pediatric Endocrine Division, MGH, Boston, MA	1992-1994
Michael Gustafson, M.D., MBA (research fellow, research mentor) "MIS as a tumor marker in women with granulosa and theca cell tumors" Pediatric Surgery, MGH, Boston, MA	1990-1993

Grants and Contracts

Current:

National Institute of General Medical Sciences (PI, Nemours, 20% effort) 09/01/2018-8/31/2023
DE-CTR ACCEL U54-GM104941 Institutional Development Award

NIEHS R01 ES014370-11 (Co-investigator, 7.5% effort) 02/01/2017 – 02/28/2021
Effects of environmental phthalates and chemical mixtures on male puberty and semen quality
(PI: R Hauser)

U13 HD067092-06 (PI) 2/1/2011-2/1/2018
Meeting grant for the American Society of Andrology Annual Meeting

Completed:

USF/Trialnet Site 3151/H12155 (PI: M Lee) 9/1/2006-5/1/2018
Univ of Southern Florida
Multi-center study on the natural history of T1DM

Helmsley Foundation (Co-investigator, 2.5% effort) 4/01/2016-3/31/2018
Type 1 Exchange (PI: D. Harlan)
Gerber Foundation/H0722 (Co-investigator, 2.5% effort) 2/10/2013-7/31/2017
Should infants with Down syndrome be screened more frequently for thyroid dysfunction?
(PI: P Feldman)

5R01 ES014370-10 (Co-Investigator, 7.5% effort) 2/1/2011-12/31/2016
Harvard School of Public Health
Dioxins, Male Pubertal Growth, and Development

BU/Helmsley Trust (Site PI; Co-investigator, 5% effort) 5/2013 – 12/2013
Testing a bi-hormonal bionic pancreas in an outpatient study in children with type 1 diabetes at the Clara Barton/Joslin Camps (PI: Ed Damiano)

NIDDK R01 DK097657 (Co-investigator, 8% effort) 2013-2015
Translational studies of a bionic pancreas for out-patient diabetes management
(PI: E Damiano and S Russell, Boston University)

NovoNordisk Research Foundation (Co-investigator) 2011-2013
Glycemic control in children and adolescents with double diabetes: trial of optimized insulin-metformin regimen (PI: B Nwosu)

NIH NR011317 (Co-investigator, 5% effort) 2010-2014
Human Patient Simulation: Parent Teaching Enhancement
(PI, S Sullivan-Bolyai)

NIAID: Immune Tolerance Network (Site PI) 2010-2014
Alpha-1 antitrypsin therapy for Type 1 DM beta cell preservation

Bristol-Meyers Squibb (PI, Lee) 4/2012–1/2014

Protocol CV181058 A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin (BMS-477118) as Monotherapy in Pediatric Patients with Type 2 Diabetes

Bristol-Meyers Squibb (PI, Lee) 4/2012 –1/2014
Protocol CV181147 A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination with Metformin IR or Metformin XR in Pediatric Patients with Type 2 Diabetes who have Inadequate Glycemic Control on Metformin Alone

NICHD R01 (PI) 2006-2012
MIS Regulation of Leydig Cell Development

Toleryx (Site Pediatric PI): 2009-2012
Defend-1: Durable-Response Therapy Evaluation for Early or New Onset T1 DM, Phase 3 trial of otelixizumab in newly dx children and adolescents with T1DM.
\$25,937 per subject
Double blind placebo control clinical trial to assess otelixumab for preservation of beta-cell function in youth with recently diagnosed T1DM (Site PI, J Mordes).

Toleryx (Site Pediatric PI) 2010-2012
TTEDD TRX-4: Therapeutic Evaluation of Different Multi-dose Regimens in Type 1 DM Phase 2 study of dosing regimens for otelixizumab.
\$45,303 per subject
Phase 2 dosing study for otelixumab for preservation of beta-cell function in youth with recently diagnosed T1DM (Site PI, J Mordes)

Toleryx (Site Pediatric PI) (Study closed due to poor efficacy data) 2010-2012
Defend-2: Durable-Response Therapy Evaluation for Early or New Onset T1 DM, Phase 3 trial of otelixizumab in newly dx children and adolescents with T1DM.

Katz Foundation (Co-investigator, 5% effort) 2009-2011
Hormonal influences on neuromaturation in girls with Bipolar Illness

DIAMYD (Co-investigator, as needed) 2009-2010
A Phase III, 3- Arm, Randomized, Placebo-controlled, Multi-center Study, to Investigate the Impact of Diamyd on the Progression of Diabetes in Patients Newly Diagnosed with Type 1 Diabetes Mellitus (TLK)

NIEHS (Co-investigator, 7.5% effort) R01 2006-2011
Dioxins and Male Pubertal Development
Prospective epidemiologic study on effect of organochlorines and heavy metals on growth and puberty in a cohort of Russian boys

NICHD (network member) 2003-2006
Psychosexual Differentiation: Biology and Socialization

Duke Provost Fund (Co-investigator) 2003-2005
Gamete preservation in females exposed to gametotoxic therapy

Trent Foundation (Co-investigator) 2002-2003
Gamete preservation in males exposed to gametotoxic therapy

EPA RO1 (Co-investigator, subcontract through Harvard School of Public Health) <i>Dioxins, Pubertal Development and Testis Function</i>	2002-2006
NICHD-K02 award (PI) <i>Developmental Control of Leydig Cells by MIS</i>	2000-2005
NICHD-R29 (PI) <i>Developmental Control of Leydig and Sertoli Cells by MIS</i>	1998-2004
NIEHS-Center Grant Pilot Project (Co-investigator) <i>Dioxins and Male Sexual Development</i>	1998-1999
Charles H. Hood Foundation (PI) <i>Regulation of Leydig Cells by MIS</i>	1997-1998
Eli Lilly and Company (co-investigator) <i>Lispro Insulin in Prepubertal Children</i>	1997-1998
American Cancer Society Pilot Grant (PI) <i>Inhibition of Leydig Cell Hyperplasia by MIS</i>	1997-1998
NIDDK- Clinical Investigator's Award (PI) <i>Transcriptional Regulation of MIS</i>	1992-1997
Genentech Foundation for Growth & Development Grant (PI) <i>MIS during Sexual Maturation</i>	1994-1996
March of Dimes Foundation Basic Research Grant (PI) <i>Developmental Regulation of MIS</i>	1992-1994
NICHD-Institutional National Research Service Award (PI) <i>Regulation of Mullerian Inhibiting Substance</i>	1991-1992
SURDNA/GAR Foundation Surgical Research Fellowship (PI) <i>Role of MIS in immune regulation</i>	1989-1991
NIDDK- Individual National Research Service Award (PI) <i>IGF Regulation of Cellular Kinases</i>	1988-1989
NIDDK-al National Research Service Award (PI) <i>Mechanism of Action of Somatomedin-c</i>	1987-1988

Publications:

Peer- reviewed publications

1. Lee MM, Welliver RC and LaScolea LJ. Campylobacter meningitis in childhood. *Pediatr Infect Dis* 1985; 4:544-547. [doi:10.1097/00006454-198509000-00021](https://doi.org/10.1097/00006454-198509000-00021)
2. Asplin CM, Faria ACS, Carlsen EC, Vaccaro VA, Barr RE, Iranamesh A, Lee MM, Veldhuis DJ and Evans WS. Alterations in the pulsatile mode of growth hormone release in men and women with insulin-dependent diabetes mellitus. *J Clin Endocrinol Metab* 1989; 69:239-245. [doi:10.1210/jcem-69-2-239](https://doi.org/10.1210/jcem-69-2-239)

3. Lee MM, Rajagopalan L, Berg GJ and Moshang T. Serum adrenal steroid concentrations in premature infants. *J Clin Endocrinol Metab* 1989; 69:1133-1136. [doi:10.1210/jcem-69-6-1133](https://doi.org/10.1210/jcem-69-6-1133)
4. Kuroda T, Lee MM, Haqq CM, Powell DM, Manganaro TF and Donahoe PK. Mullerian inhibiting substance ontogeny and modulation by FSH in rat testes. *Endocrinology* 1990; 127:1825-1832. [doi:10.1210/endo-127-4-1825](https://doi.org/10.1210/endo-127-4-1825)
5. Epstein J, Lee MM, Kelly CE and Donahoe PK. Effect of E. Coli endotoxin on mammalian cell growth and recombinant protein production. *In Vitro Cell Dev Biol* 1990; 26:1121-11 [doi:10.1007/BF02623686](https://doi.org/10.1007/BF02623686)
6. Kuroda T, Lee MM, Hirobe S, Ragin RC, Donahoe PK. Mullerian inhibiting substance production and cleavage is modulated by gonadotropins and steroids. *Endocrinology* 1991; 129:2985-2992. [doi:10.1210/endo-129-6-2985](https://doi.org/10.1210/endo-129-6-2985)
7. Lee MM, Cate R, Donahoe PK and Waneck GL. Developmentally regulated polyadenylation of two discrete mRNAs for Mullerian inhibiting substance. *Endocrinology* 1992; 130:847-853. [doi:10.1210/en.130.2.847](https://doi.org/10.1210/en.130.2.847)
8. Gustafson ML, Lee MM, Scully RE, Moncure AC, Hirakawa T, Goodman A, Muntz HG, Donahoe PK, MacLaughlin DT and Fuller AF. Mullerian inhibiting substance as a marker for ovarian sex-cord tumor. *New Engl J Med* 1992; 326:466-471. [doi:10.1056/NEJM199202133260707](https://doi.org/10.1056/NEJM199202133260707)
9. Haqq C, Lee MM, Tizard R, Wyst M, DeMarinas J, Donahoe PK and Cate RL. Isolation of the rat gene for Mullerian inhibiting substance. *Genomics* 1992; 12:665-669. [doi:10.1016/0888-7543\(92\)90291-Y](https://doi.org/10.1016/0888-7543(92)90291-Y)
10. Hartman ML, Veldhuis JD, Johnson ML, Lee MM, Alberti KGMM, Samojlik E and Thorner MO. Augmented growth hormone (GH) secretory burst frequency and amplitude mediate enhanced GH secretion during a two-day fast in normal men. *J Clin Endocrinol Metab* 1992; 74:757-765. [doi:10.1210/jc.74.4.757](https://doi.org/10.1210/jc.74.4.757)
11. Hirobe S, He WW, Lee MM and Donahoe PK. Mullerian inhibiting substance messenger ribonucleic acid expression in granulosa and Sertoli cells coincides with their mitotic activity. *Endocrinology* 1992; 131:854-862. [doi:10.1210/en.131.2.854](https://doi.org/10.1210/en.131.2.854)
12. Gustafson ML, Lee MM, Asmundson L, MacLaughlin DT and Donahoe PK. Mullerian Inhibiting Substance in the diagnosis and management of intersex and gonadal abnormalities. *J Ped Surg* 1993; 28:439-444. [doi:10.1016/0022-3468\(93\)90245-G](https://doi.org/10.1016/0022-3468(93)90245-G)
13. Meyers-Wallen VN, Lee MM, Manganaro TF, Kuroda T, MacLaughlin DT and Donahoe PK. Mullerian Inhibiting Substance is present in embryonic testes of dogs with persistent Mullerian duct syndrome. *Biol Reprod* 1993; 48:1410-1418. [doi:10.1095/biolreprod48.6.1410](https://doi.org/10.1095/biolreprod48.6.1410)
14. Lee MM, Gustafson ML, Wexler M, Donahoe PK, MacLaughlin DT and Keeping HS. Developmental changes in mullerian inhibiting substance in the cynomolgus monkey, *Macaca fascicularis*. *J Clin Endocrinol Metab* 1994; 78:615-621. [doi:10.1210/jc.78.3.615](https://doi.org/10.1210/jc.78.3.615)
15. New England Congenital Hypothyroidism Collaborative*. Correlation of cognitive test scores and adequacy of treatment in adolescents with congenital hypothyroidism. *J Pediatr* 1994; 124: 383-387 (*member of collaborative). [doi:10.1016/S0022-3476\(94\)70359-0](https://doi.org/10.1016/S0022-3476(94)70359-0)
16. Lee MM, Donahoe PK, Hasegawa T, Silverman B, Crist G, Best S, Noto R, Hasegawa Y and MacLaughlin DT. Mullerian Inhibiting Substance (MIS) in humans: Normal levels from infancy to adulthood. *J Clin Endocrinol Metab* 1996; 81:571-576. [doi:10.1210/jc.81.2.571](https://doi.org/10.1210/jc.81.2.571)
17. Teixeira J, He WW, Shah, PC, Morikawa N, Lee MM, Catlin EA, Hudson PL, Wing J, MacLaughlin DT and Donahoe PK. Developmental expression of a candidate Mullerian inhibiting substance type II receptor. *Endocrinology* 1996; 137:160-165. [doi:10.1210/en.137.1.160](https://doi.org/10.1210/en.137.1.160)
18. Lee MM, Donahoe PK, Silverman B, Hasegawa T, Hasegawa Y, Gustafson ML, Chang YC, and MacLaughlin DT. Measurements of serum Mullerian Inhibiting Substance in the evaluation of children with nonpalpable gonads. *New Engl J Med* 1997; 336:1480-1486. [doi:10.1056/NEJM199705223362102](https://doi.org/10.1056/NEJM199705223362102)
19. Lane AH, Lee MM, Fuller AF, Kehas D, Donahoe PK, MacLaughlin DT. Diagnostic utility of Mullerian inhibiting substance determination in patients with primary and recurrent granulosa cell tumors. *Gynecol Oncol* 1999; 73:51-55. [doi:10.1006/gyno.1998.5290](https://doi.org/10.1006/gyno.1998.5290)

20. Lee MM, Seah CC, Masiakos P, Sottas C, Preffer F, Donahoe PK, MacLaughlin DTM, and Hardy MP. Mullerian inhibiting substance type II receptor expression and function in primary rat Leydig cells. *Endocrinology* 1999; 140:2819-2827. [doi:10.1210/en.140.6.2819](https://doi.org/10.1210/en.140.6.2819)
21. Sergeyevo O, Zeilert V, Revich B, Ushakova T, Williams P, Korrick S, Lee MM, Altshul L, Adibi J and Hauser R. Sexual and physical maturation of male adolescents in a dioxin contaminated region: Chapaevsk, Russia. *Organohalogen Compounds* 2000; 48:211-214.
22. Sriraman V, Niu E, Matias JR, Donahoe PK, MacLaughlin DT, Hardy MP and Lee MM. Mullerian Inhibiting Substance inhibits testosterone synthesis in adult rats. *J Androl* 2001; 22:750-758. [doi:10.2164/jandrol.110.012815](https://doi.org/10.2164/jandrol.110.012815)
23. Misra M, Levitsky LL, and Lee MM. Transient hyperthyroidism in an adolescent with hydatidiform mole. *J Pediatr* 2002; 140:362-366. [doi:10.1067/mpd.2002.120514](https://doi.org/10.1067/mpd.2002.120514)
24. Misra M, MacLaughlin DT, Donahoe PK and Lee MM. Measurement of MIS facilitates management of boys with microphallus and cryptorchidism. *J Clin Endocrinol Metab* 2002; 87:3598-3602. [doi:10.1210/jc.87.8.3598](https://doi.org/10.1210/jc.87.8.3598)
25. Litton J, Rice A, Friedman N, Oden J, Lee MM and Freemark M. Insulin pump therapy in infants and preschool children with type 1 diabetes mellitus. *J Pediatrics* 2002; 141:490-495. [doi:10.1067/mpd.2002.127500](https://doi.org/10.1067/mpd.2002.127500)
26. Misra M, MacLaughlin DT, Donahoe PK and Lee MM. The role of Mullerian inhibiting substance in the evaluation of phenotypic females with mild degrees of virilization. *J Clin Endocrinol Metab* 2003; 88:787-797. [doi:10.1210/jc.2002-020889](https://doi.org/10.1210/jc.2002-020889)
27. Lee MM, Sergeyevo O, Williams P, Korrick S, Zeilert V, Revich B, and Hauser R. Physical growth and sexual maturation of boys in Chapaevsk, Russia. *J Pediatric Endocrinol* 2003; 16: 169-178. [doi:10.1515/JPEM.2003.16.2.169](https://doi.org/10.1515/JPEM.2003.16.2.169)
28. Lee MM, Misra M, Donahoe PK and MacLaughlin DT. MIS/AMH in the assessment of cryptorchidism and intersex conditions. *Mol Cell Endocrinol* 2003; 211:91-98. [doi:10.1016/j.mce.2003.09.014](https://doi.org/10.1016/j.mce.2003.09.014)
29. Hardy O, Worley G, Lee MM, Chaing S, Mackey J, Crissman B, and Kishnani PS. Hypothyroidism in Down Syndrome: Screening guidelines and testing methodology. *Am J Med Genet* 2004; 124A:436-437. [doi:10.1002/ajmg.a.20356](https://doi.org/10.1002/ajmg.a.20356)
30. Salva A, Hardy MP, Wu XF, Sottas CM, MacLaughlin DT, Donahoe PK, and Lee MM. Mullerian Inhibiting Substance prevents rat Leydig cell degeneration after ethylene dimethanesulphonate (EDS) ablation. *Biol Reprod* 2004; 70:600-607 (first published on-line October 29, 2003). [doi:10.1095/biolreprod.103.021550](https://doi.org/10.1095/biolreprod.103.021550)
31. Hauser R, Williams P, Altshul L, Korrick S, Peeples L, Patterson D, Turner WE, Lee MM, Revich B, Zeilert V, and Sergeyevo O. Characterization and predictors of serum dioxin levels among adolescent boys in Chapaevsk, Russia. *Organohalogen Compounds* 2004; 66:3245-3251.
32. Wu XF, Arumugam R, Baker SP, and Lee MM. Pubertal and adult Leydig cell function in Mullerian Inhibiting Substance (MIS/AMH) deficient mice. *Endocrinology* 2005; 146:589-595 (first published on-line October 28, 2004). [doi: 10.1210/en.2004-0646](https://doi.org/10.1210/en.2004-0646)
33. Hauser R, Williams P, Altshul L, Korrick S, Peeples L, Patterson D, Turner WE, Lee MM, Revich B, Zeilert V, and Sergeyevo O. Predictors of serum dioxin levels among adolescent boys in Chapaevsk, Russia: A cross-sectional study. *Environmental Health: A Global Access Science Source* 2005; 4/1/8 (<http://www.ehjournal.net/content/4/1/8>). [doi: 10.1186/1476-069X-4-8](https://doi.org/10.1186/1476-069X-4-8)
34. Quigley DI, McDonald MT, Krishnamuthy V, Krishnani PS, Lee MM, Haqq AM, and Goodman BK. Triploid Mosaicism in a 45, X/69, XXY Infant. *Am J Med Gen* 2005; 138A:171-174. [doi:10.1002/ajmg.a.30943](https://doi.org/10.1002/ajmg.a.30943)
35. Burns JS, Williams PL, Sergeyevo O, Gitin E, Denisova T, Korrick S., Lee MM, Revich B, Altshul L, Patterson DG. Local dietary contributions to serum dioxins, furans, and polychlorinated biphenyls in peri-pubertal Russian boys. *Epidemiology* 2006; 17:S138-9 ISEE/ISEA 2006 Conference Abstracts
36. Buchold GM, Magyar PL, Arumugam R, Lee MM, and O'Brien DA. p19Ink4d and p18Ink4c cyclin-dependent kinase inhibitors in the male reproductive axis. *Mol Reprod Dev* 200; 74(8):997-1007 (Pub Online: 6 Mar 2007). [doi:10.1002/mrd.20716](https://doi.org/10.1002/mrd.20716)

37. Burns JS, Williams PL, Sergeyev O, Gitin E, Lee MM, Korrick S, Revich B. Blood lead levels and reported mood symptoms among Russian boys. *Epidemiology* 2007; 18(5):S91. [doi:10.1097/01.ede.0000288376.88588.6f](https://doi.org/10.1097/01.ede.0000288376.88588.6f)
38. Wu XF, Wan SQ, and Lee MM. Key factors in the regulation of fetal and postnatal Leydig cell development. *J Cell Physiol* 2007; 213:429-433. [doi:10.1002/jcp.21231](https://doi.org/10.1002/jcp.21231)
39. Hauser R, Sergeyev O, Korrick S, Lee MM, Revich B, Gitin E, Burns J, and Williams P. Association of blood lead levels with onset of puberty in Russian boys. *Environmental Health Persp* 2008; 116 (7) 976-980. [doi:10.1289/ehp.10516](https://doi.org/10.1289/ehp.10516)
40. Burns JS, Williams PL, Sergeyev O, Korrick S, Lee MM, Revich B, Altshul L, Turner WE, Patterson DG, Saharov I, Hauser R. Predictors of serum Dioxins and PCBs in a Russian cohort of boys. *Organohalogen Compounds* 2008; 70:1490-1493.
41. Nwosu, B, Soyka LA, Angelescu A, Hardy OT, and Lee, MM. Multifetal Pregnancy may increase the risk for Severe Maternal and Neonatal Vitamin D Deficiency. *Endocrinologist* 2008; 18:172-174. [doi:10.1097/TEN.0b013e3181815a9e](https://doi.org/10.1097/TEN.0b013e3181815a9e)
42. Wu XF, Wan SQ, Pujar S, Haskins ME, Schlafer DH, Lee MM and Meyers-Wallen VN. A single base pair mutation encoding a premature stop codon in the MIS type II receptor is responsible for canine Persistent Müllerian Duct Syndrome. *J Andrology* 2009; 30:46-56. [doi:10.2164/jandrol.108.005736](https://doi.org/10.2164/jandrol.108.005736)
43. Nwosu BU, Soyka LA, Angelescu A, Hardy OT, Lee MM. Do atypical antipsychotic agents trigger autoimmune diabetes in adolescents? *The Endocrinologist* 2009; 19:85-87. [doi:10.1097/TEN.0b013e318198b9b8](https://doi.org/10.1097/TEN.0b013e318198b9b8)
44. Nwosu BU and Lee MM. Pseudohypoparathyroidism type 1a and insulin resistance in a child. *Nature Rev Endocrinol* 2009; 5:345-350. [doi:10.1038/nrendo.2009.81](https://doi.org/10.1038/nrendo.2009.81)
45. Burns JS, Williams PL, Sergeyev O, Korrick S, Lee MM, Revich B, Altshul L, Patterson Jr, DG, Turner WE, Needham LL, Saharov I, and Hauser R. Predictors of Serum Dioxins and PCBs among Peri-Pubertal Russian Boys. *Environmental Health Persp* 2009; 117:1593-9. [doi:10.1289/ehp.0800223](https://doi.org/10.1289/ehp.0800223)
46. Sullivan-Bolyai S, Bova C, Leung K, Trudeau A, Lee MM, and Gruppuso P. Social Support To Empower Parents (STEP): An intervention for parents of young children newly diagnosed with type 1 diabetes. *Diabetes Educator* 2010; 36:88-97. [doi:10.1177/0145721709352384](https://doi.org/10.1177/0145721709352384)
47. Williams PL, Sergeyev O, Lee MM, Korrick S, Burns JS, Humblet O, DelPrato J, Revich B, and Hauser R. Blood lead levels and delayed onset of puberty in a longitudinal study of Russian boys. *Pediatrics* 2010; 125: e1088-e1096. [doi:10.1542/peds.2009-2575](https://doi.org/10.1542/peds.2009-2575)
48. Burns JS, Williams PL, Sergeyev O, Korrick S, Lee MM, Revich B, Altshul L, Patterson DG Jr, Del Prato JT, Humblet O, Starovoytov M, Saharov I, and Hauser R. Dioxins and PCBs among Russian boys: predictors of serum levels and associations with childhood growth. 30th International Symposium on Halogenated Persistent Organic Pollutants (POPs), September 12-17, 2010, San Antonio, TX. CD-ROM.
49. Burns JS, Williams PL, Sergeyev O, Korrick S, Lee MM, Revich B, Altshul L, Patterson DG Jr, Del Prato JT, Humblet O, Starovoytov M, and Hauser R. Associations of serum concentrations of chlorinated pesticides with longitudinal growth in a Russian cohort of boys. 30th International Symposium on Halogenated Persistent Organic Pollutants (POPs), September 12-17, 2010, San Antonio, TX. CD-ROM.
50. Wu XF, Arumugam R, Zhang NN, and Lee MM. Androgen profiles during pubertal Leydig cell development in the mouse. *Reproduction* 2010; 140:113-12. [doi:10.1530/REP-09-0349](https://doi.org/10.1530/REP-09-0349)
51. Humblet O, Williams PL, Korrick SA, Sergeyev O, Emond C, Birnbaum LS, Burn JS, Altshul L, Patterson Jr DG, Turner WE, Lee MM and Hauser R. Predictors of serum dioxin, furan and PCB concentrations among women from Chapaevsk, Russia. *Environmental Sci Tech* 2010; 44(14):5633-40. [doi:10.1021/es100976j](https://doi.org/10.1021/es100976j)
52. Burns JS, Williams PL, Sergeyev O, Korrick S, Lee MM, Revich B, Altshul L, Del Prato JT, Humblet O, Patterson DG, Turner WE, Needham LL, Starovoytov M and Hauser R. Serum dioxins and polychlorinated biphenyls are associated with growth among Russian Boys. *Pediatrics* 2011; 127:e59-68 (published on-line December 27, 2010. [doi:10.1542/peds.2008-3556](https://doi.org/10.1542/peds.2008-3556).

53. Sullivan-Bolyai S and Lee MM. Parent mentor perspectives on providing social support to empower parents (STEP). *Diabetes Educator* 2011; 37:35-43. [doi: 10.1177/0145721710392248](https://doi.org/10.1177/0145721710392248)
54. Nwosu BU, Soyka LA, Angelescu A and Lee MM. Evidence of insulin-like growth factor binding protein-3 proteolysis during growth hormone stimulation testing. *J Pediatr Endocr Metab* 2011; 24:163-167. [doi:10.1515/JPEM.2011.022](https://doi.org/10.1515/JPEM.2011.022).
55. Sullivan-Bolyai S, Bova C, Lee MM, and Gruppuso PA. Mentoring fathers of children newly diagnosed with T1DM. *Am J Matern Child Nurs* 2011; 36:224-231. [doi: 10.1097/NMC.0b013e3182183bf5](https://doi.org/10.1097/NMC.0b013e3182183bf5).
56. Korricks S, Lee MM, Williams PL, Sergeev O, Burns JS, Patterson Jr, DG, Turner WE, Needham LL, Altshul L, Revich B, and Hauser R. Dioxin exposure and age of pubertal onset among Russian boys. *Environmental Health Persp* 2011; 119(9): 1339–1344 (published on-line April 28, 2011) [doi:10.1289/ehp.1003102](https://doi.org/10.1289/ehp.1003102).
57. Humblet O, Sergeev O, Altshul L, Korricks SA, Williams PL, Emond C, Birnbaum LS, Burns JS, Lee MM, Revich B, Shelepchikov A, Feshin D, Hauser R. Temporal trends in serum concentrations of polychlorinated dioxins, furans, and PCBs among adult women living in Chapaevsk, Russia: a longitudinal study from 2000 to 2009. *Environ Health* 2011; 10:62. [doi: 10.1186/1476-069X-10-62](https://doi.org/10.1186/1476-069X-10-62)
58. Humblet O, Williams PL, Korricks SA, Sergeev O, Emond C, Birnbaum LS, Burns JS, Altshul L, Patterson DG, Turner WE, Lee MM, Revich B, Hauser R. Dioxin and PCB concentrations in mothers' serum and the timing of pubertal onset in sons. *Epidemiology* 2011; 22:827-835. [doi: 10.1097/EDE.0b013e318230b0d1](https://doi.org/10.1097/EDE.0b013e318230b0d1).
59. Marvin L. Mitchell, Ho-Wen Hsu, Inderneel Sahai and the Massachusetts Pediatric Endocrine Work Group. The increased incidence of congenital hypothyroidism: fact or fancy? *Clinical Endocrinology* 2011; 75, 806–810. [doi:10.1111/j.1365-2265.2011.04128](https://doi.org/10.1111/j.1365-2265.2011.04128)
60. Nwosu BU, Meltzer B, Maranda L, Ciccarelli C, Reynolds D, Curtis C, King J, Frazier J, and Lee MM. A potential role for adjunctive vitamin D therapy in the management of weight gain and metabolic side effects of second generation antipsychotics. *J Pediatric Endocrinol Metab* 2011; 24: 619-626. [doi:10.1515/JPEM.2011.300](https://doi.org/10.1515/JPEM.2011.300)
61. Sullivan-Bolyai S, Crawford, S, Johnson K, Huston B, and Lee MM. Educating diabetes camp counselors with a human patient simulator: A pilot study. *J Specialists Pediatr Nursing* 2012; 17(2):121-8. [doi: 10.1111/j.1744-6155.2011.00322.x](https://doi.org/10.1111/j.1744-6155.2011.00322.x).
62. Burns JS, Williams PL, Sergeev O, Korricks S, Lee MM, Revich B, Altshul L, Del Prato JT, Humblet O, Patterson DG, Turner WE, Starovoytov M and Hauser R. Serum concentrations of organochlorine pesticides and growth among Russian boys. *Environmental Health Persp* 2012; 120:303-308. (published online 7 October 2011) [doi:10.1289/ehp.1103743](https://doi.org/10.1289/ehp.1103743).
63. Sullivan-Bolyai S, Bova C, and Lee MM. Development and Pilot Testing of a Parent Education Intervention for T1DM: PETS-D (Parent Education through Simulation-Diabetes). *The Diabetes Educator* 2012; 38(1):50-7. [doi:10.1177/0145721711432457](https://doi.org/10.1177/0145721711432457)
64. Nwosu BU, Stavre Z, Maranda L, Cullen CA, and Lee MM. Hepatic dysfunction is associated with vitamin D deficiency and poor glycemic control in diabetes mellitus. *J Pediatric Endocrinol Metab* 2012; 25:181-186. [doi:10.1515/jpem-2011-0403](https://doi.org/10.1515/jpem-2011-0403)
65. English RG, Dalvie MA, Perry M, Lee MM, Hoffman E, Delport S, and London L. Farm residence and reproductive health amongst among boys in rural South Africa. *Environment International*; 2012, 47: 73-79. [doi:10.1016/j.envint.2012.06.006](https://doi.org/10.1016/j.envint.2012.06.006).
66. Burns JS, Williams PL, Lee MM, Sergeev O, Korricks SA, Fleisch AF, Hauser R. Association of Serum Dioxin-like Compounds with Serum Lipids in Russian Boys. *Am J Epidemiol*. 2012; 175 (Supp 11): S49.
67. Wu, XF, Zhang, NN, and Lee MM. Mullerian inhibiting substance recruits ALK3 to regulate Leydig cell differentiation. *Endocrinology* 2012 (published on-line August 7, 2012); [doi: 10.1210/en.2012-1168](https://doi.org/10.1210/en.2012-1168).
68. Humblet O, Korricks SA, Williams PL, Sergeev O, Edmond C, Birnbaum LS, Burns JS, Altshul LM, Patterson DG Jr, Turner WE, Lee MM, Revich B, Hauser R. Genetic modification of the association between peripubertal dioxin exposure and pubertal onset in a cohort of Russian boys. *Environ Health Perspect* 2013; 121(1):111-117. PMID: PMC3546349.

69. Fleisch AF, Burns JS, Williams PL, Lee MM, Sergeev O, Korrick SA, and Hauser, R. Blood lead levels and serum insulin-like growth factor 1 concentrations in peripubertal boys. *Environ Health Perspectives* 2013; (Published on-line April 26, 2013) [doi: 10.1289/ehp.1206105](https://doi.org/10.1289/ehp.1206105)
70. Mitchell K, Schnyder S, Johnson K, Cullen K, Lee MM, Hardy O. Parental mastery of continuous subcutaneous insulin infusion skills and glycemic control in youth with type 1 diabetes. *Diabetes Tech Therapeutics*. 2013; 15:591-595. [doi: 10.1089/dia.2013.0031](https://doi.org/10.1089/dia.2013.0031).
71. Nwosu BU, Cullen K, Ciccarelli C, Maranda L, Lee MM. The relationship between vitamin D status and early markers of cardiovascular disease in prepubertal children. *J Pediatr Endocrinol Metab* 2013; 26(11-12):1067-75. [doi: 10.1515/jpem-2013-0086](https://doi.org/10.1515/jpem-2013-0086)
72. Lam T, Williams PL, Burns JS, Sergeev O, Korrick S, Lee MM, Birnbaum LS, Revich B, Altshul L, Patterson DG Jr., Turner WE, Hauser R. Predictors of serum chlorinated pesticide concentrations among pre-pubertal Russian boys. *Environ Health Perspect* 2013; 121(11-12):1372-1377. [doi:10.1289/ehp.1306480](https://doi.org/10.1289/ehp.1306480).
73. Lam T, Williams PL, Lee MM, Korrick SA, Birnham LS, Burns JS, Sergeev O, Revich B, Altshul LM, Patterson DG Jr., Hauser R. Prepubertal organochlorine pesticide concentrations and age of pubertal onset among Russian boys. *Environ International* 2014; 73:135-142. [doi: 10.1016/j.envint.2014.06.020](https://doi.org/10.1016/j.envint.2014.06.020), Epub 2014 Aug 10. PMID: PMC4194160.
74. Burns JS, William PL, Korrick SA, Hauser R, Sergeev O, Revich B, Lam T, Lee MM. Association between chlorinated pesticides in the serum of prepubertal Russian boys and longitudinal biomarkers of metabolic function. *Am J Epidemiol* 2014; 180:909-919. [doi: 10.1093/aje/kwu212](https://doi.org/10.1093/aje/kwu212)
75. Sullivan-Bolyai S, Bova C, Johnson K, Cullen K, Jaffarian C, Quinn D, Aroke EN, Crawford S, Lee MM and Gupta O. Engaging teens and parents in collaborative practice: perspectives on diabetes self-management. *The Diabetes Educator* 2014; 40:178-190. [doi: 10.1177/0145721713520568](https://doi.org/10.1177/0145721713520568).
76. Moore Simas TA, Corvera S, Lee MM, Zhang N, Leung, K, Olendski B, Barton B, Rosal M. Understanding multifactorial influences on the continuum of maternal weight trajectories in pregnancy and early postpartum: study protocol, and participant baseline characteristics. *BMC Pregnancy and Childbirth* 2015; 15:71. [doi: 10.1186/s12884-015-0490-7](https://doi.org/10.1186/s12884-015-0490-7).
77. Sullivan-Bolyai S, Crawford S, Bova C, Lee MM, Quintos JB, Johnson K, Cullen K, Hamm T, Bisordi J, Ramchandani N, Fletcher J, Quinn D, Jaffarian C, Lipman T, and Melkus G. PETS-D impact on diabetes management outcomes. *The Diabetes Educator* 2015; 41:537-549. [doi: 10.1177/0145721715598383](https://doi.org/10.1177/0145721715598383).
78. Lam T, Williams PL, Lee MM, Korrick SA, Birnbaum LS, Burns JS, Sergeev O, Revich B, Altshul LM, Patterson DG Jr, and Hauser R. Prepubertal serum concentrations of organochlorine pesticides and age at sexual maturity in Russian boys. *Environ Health Perspect* 2015; 123:1216-1221, Epub May 22. [doi:10.1289/ehp.1409022](https://doi.org/10.1289/ehp.1409022). PMID:26009253 PMID:PMC4629743.
79. Ramchandani N., Maguire L. L., Stern K., Quintos J. B., Lee MM., and Sullivan-Bolyai S. PETS-D (Parents Education Through Simulation - Diabetes): Parents' qualitative results. *Patient Educ Counsel* 2016: (e-pub ahead of print) [doi: 10.1016/j.pec.2016.03.019](https://doi.org/10.1016/j.pec.2016.03.019).
80. Mitchell ML, Hu HW and the Massachusetts Pediatric Endocrine Work Group (Lee, MM, Member). Commentary: Unresolved Issues in the wake of newborn screening for congenital hypothyroidism. *J Pediatr* 2016; 173:228-231.
81. Burns JS, Lee MM., Williams PL, Korrick, SA, Sergeev O, Lam T, Revich B and Hauser R. Associations of peripubertal serum dioxin and polychlorinated biphenyl concentrations with pubertal timing among Russian boys. *Environ Health Perspect* 2017; 124:1801-1807. .
82. Minguez-Alarcon L, Sergeev O, Burns JS, Williams PL, Lee MM, Korrick SA, Smigulina L, Revich B and Hauser R. A longitudinal study of peripubertal serum organochlorine concentrations and semen parameters in young men: The Russian Children's Study. *Environ Health Perspect* 2017; 125, 460-466.
83. Burns JS, Williams PL, Lee MM, Revich B, Sergeev O, Hauser R and Korrick SA. Peripubertal blood lead levels and growth among Russian boys. *Environ Int* 2017; 106:53-59. [doi:10.1016/j.envint.2017.05.023](https://doi.org/10.1016/j.envint.2017.05.023).

84. Creo AL, Candela N, Lee MM, Feldman PM. An unusual manifestation of celiac disease in an adolescent with down syndrome and Graves disease. *J Pediatric Gastroenterology and Nutrition* 2017; 65(1):e20–e22, 2017. doi: [10.1097/MPG.0000000000000858](https://doi.org/10.1097/MPG.0000000000000858).
85. Huang L, Liu J, Zhang XO, Sibley K, Najjar SM, Lee MM, Wu Q. Inhibition of protein arginine methyltransferase 5 enhances hepatic mitochondrial biogenesis. *J Biol Chem*. 2018 May doi: [10.1074/jbc.RA118.002377](https://doi.org/10.1074/jbc.RA118.002377). [Epub ahead of print]

Invited publications or reviews

1. Moshang T and Lee MM. Late effects: Disorders of growth and sexual maturation associated with the treatment of childhood cancer. *J Pediatr Oncology Nurses* 1988; 5:14-19. doi: [10.1177/104345428800500405](https://doi.org/10.1177/104345428800500405).
2. Donahoe PK, Lee MM, Powell DM. Clinical Management of Intersex Abnormalities. *Curr Probl Surg* 1991; 28:515-579. PMID: 1884628
3. Lee MM and Donahoe PK. Mullerian Inhibiting Substance: a gonadal hormone with multiple functions. *Endo Rev* 1993; 14:152-164. doi: [10.1210/edrv-14-2-152](https://doi.org/10.1210/edrv-14-2-152).
4. Lane A and Lee MM. Clinical applications of Mullerian inhibiting substance in patients with gonadal disorders. *The Endocrinologist* 1999; 9:208-215. doi: [10.1097/00019616-199905000-00007](https://doi.org/10.1097/00019616-199905000-00007)
5. Lane A and Lee MM. Mullerian Inhibiting Substance: a nontraditional marker of gonadal function. *Current Op Endocrinol Diabetes* 2001; 8:296-300. doi: [10.1097/00060793-200112000-00006](https://doi.org/10.1097/00060793-200112000-00006)
6. Lee MM. Idiopathic short stature. *New Engl J Med* 2006; 354:2576-2582. doi: [10.1056/NEJMcp060828](https://doi.org/10.1056/NEJMcp060828)
7. Nwosu B and Lee MM. Evaluation of Short and Tall Stature in Children. *Am Fam Physician* 2008; 78(5):597-604. PMID: 18788236.
8. Jacobson-Dickman E and Lee MM. The influence of endocrine disrupting compounds on pubertal timing. *Current Op Endocrinol Diab Obesity* 2009; 16:25-30. doi: [10.1097/MED.0b013e328320d560](https://doi.org/10.1097/MED.0b013e328320d560)
9. Nwosu BU, Lee MM. Evaluation of Tall and Short Stature in Children. *Pediatrics for Parents* 2010; 25:22-24. PMID: 18788236
10. Zawatski W and Lee MM. Male pubertal development: are endocrine disrupting compounds shifting the norms? *J Endocrinol* 2013; 218(2):R1-12. doi: [10.1530/JOE-12-0449](https://doi.org/10.1530/JOE-12-0449).
11. Sergeev O, Burns JS, Williams PL, Korrick SA, Lee MM, Revich B. and Hauser R. The association of peripubertal serum concentrations of organochlorine chemicals and blood lead with growth and pubertal development in a longitudinal cohort of boys: A review of published results from the Russian Children’s Study. *Reviews on Environmental Health* 2017; 32, 83-92. doi: [10.1515/reveh-2016-0052](https://doi.org/10.1515/reveh-2016-0052).
12. Greenspan, LC and Lee MM. Endocrine disruptors and pubertal timing. *Curr Opin Endocrinol Diabetes Obes* 2018; 25:45-54.

Editorials, Position and Background Papers

1. Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. Guidelines for the use of growth hormone in children with short stature. *J Pediatr* 1995; 127:857-867. doi: [10.1016/S0022-3476\(95\)70019-6](https://doi.org/10.1016/S0022-3476(95)70019-6).
2. Lee MM. Is LHRHa therapy justified in short adolescents? (Editorial) *New Engl J Med* 2003; 348: 942-945. doi: [10.1056/NEJMe030003](https://doi.org/10.1056/NEJMe030003).
3. Lee MM. Reproductive hormones in infant girls: a harbinger of adult reproductive function? (Editorial) *J Clin Endocrinol Metab* 2003; 88:3513-3514. doi: [10.1210/jc.2003-031038](https://doi.org/10.1210/jc.2003-031038).
4. Lee MM. Commentary on the New Engl J Med article “Treatment with Luteinizing hormone-releasing hormone agonist in adolescents with short stature.” *J Pediatr* 2003; PMID: 12621135

5. Lee MM. Editorial commentary on "Urinary prostate-specific antigen is a noninvasive indicator of sexual development in male children." J Androl 2007; 28:155-157. [doi: 10.2164/jandrol.106.001891](https://doi.org/10.2164/jandrol.106.001891)
6. Carel JC, Eugster EA, Rogol A, Ghizzoni L, and Palmert MR (on behalf of the ESPE-LWPES GnRH analogs consensus conference group). Consensus Statement on the Use of GnRH Analogs in Children. Pediatrics 2009; 123:e752-e762. [doi: 10.1542/peds.2008-1783](https://doi.org/10.1542/peds.2008-1783).
7. Harlan DM and Lee MM. Infant Formula, Autoimmune triggers, and Type 1 Diabetes Mellitus (Editorial) New Engl J Med 2010; 363: 1961-1963. [doi:10.1056/NEJMe1010654](https://doi.org/10.1056/NEJMe1010654)

Books and Chapters

1. Lee MM, Cara JF and Moshang T. "Endocrinology." in Schwartz MW, ed. Principles and Practice of Pediatric Primary Care. Chicago: Yearbook Medical Publishers, Inc. 1989; 1410-1431.
2. Donahoe PK and Lee MM. "Ambiguous Genitalia" in Barden W, ed. Current Therapy in Endocrinology and Metabolism, 4th Ed. Philadelphia: B. C. Decker, Inc. 1991; 232-240.
3. Lee MM, Kuroda T and Donahoe PK. "Mullerian Inhibiting Substance" in Desjardins C and Ewing LL, eds. Cell and Molecular Biology of the Testis. New York: Oxford University Press, Inc. 1993; 108-126.
4. Lee MM and Donahoe PK. "The Infant with Ambiguous Genitalia" in Barden W, ed. Current Therapy in Endocrinology and Metabolism, 5th Ed. Philadelphia: B. C. Decker, Inc 1994; 242-249.
5. Lee MM and Levitsky LL. "Tall Stature" In Burg FD, Ingelfinger JR, Wald ER, and Polin RA, eds. Current Pediatric Therapy, 15th Ed. Philadelphia: W. B. Saunders 1996; 332-334.
6. Lee MM and Donahoe PK. "The Infant with Ambiguous Genitalia" in Barden W, ed. Current Therapy in Endocrinology and Metabolism, 5th Ed. Philadelphia: B. C. Decker, Inc. 1997; 216-223.
7. Weinzimer SA, Lee MM, and Moshang TM. "Endocrinology," in Schwartz MW, Curry TA, Sargent AJ, Blum NJ, and Fein JA, eds. Pediatric Primary Care: A Problem-Oriented Approach, 3rd Ed. St. Louis: Mosby-Year Book, Inc. 1997; 529-541.
8. Lane A, Lee MM, and Donahoe PK. "Anatomic Abnormalities of the Female Reproductive Tract," in Burg FD, Ingelfinger JR, Wald ER, and Polin RA, eds. Current Pediatric Therapy, 16th Ed. Philadelphia: W. B. Saunders 1999; 829-832.
9. Soyka L and Lee MM. "Turners Syndrome" in Burg FD, Ingelfinger JR, Wald ER, and Polin RA, eds. Current Pediatric Therapy, 16th Ed. Philadelphia: W. B. Saunders, 1999, 529-541.
10. Lee MM. "Genitalia," in Knobil E and Neill J, eds. The Encyclopedia of Reproduction. San Diego: Academic Press, Inc. 1999; 439-444.
11. Teixeira J and Lee MM. "Male Gonadogenesis," in Knobil E and Neill J, eds. The Encyclopedia of Reproduction. San Diego: Academic Press, Inc. 1999; 492-497.
12. Catlin EA and Lee MM. "Neonatal endocrinology," in DeAngelis CD, Feigin RD, McMillan JA, and Warshaw JB, eds. Oski's Pediatrics: Principles and Practice, 3rd ed. Philadelphia: Lippincott Williams & Wilkins 1999; 345-356.
13. Lee MM. "MIS Actions in the Developing Testis," in E. Goldberg, ed. The Testis: From Stem Cell to Sperm Function. New York: Springer-Verlag New York, Inc. 2000; 30-42.
14. Misra M and Lee MM. "Gonadal disorders," in Burg FD, Ingelfinger JR, Gershon A, and Polin RA, eds. Current Pediatric Therapy, 17th Ed. Philadelphia: W. B. Saunders, 2002; 698-704.
15. Lee MM and Levitsky LL. "Adrenal disorders," In Burg FD, Ingelfinger JR, Gershon A, and Polin RA, eds. Current Pediatric Therapy, 17th Ed. Philadelphia: W. B. Saunders 2002; 693-698.
16. Lee MM. "Molecular Genetic Control of Sex Differentiation," in Eugster EA and Pescovitz OH, eds. Pediatric Endocrinology: Mechanisms, Manifestations and Management. Philadelphia: Lippincott, Williams and Wilkins 2004, 231-242.
17. Misra M and Lee MM. "Delayed puberty," in Moshang T., ed. Requisites in Pediatric Endocrinology. Philadelphia: W. B. Saunders 2005; 87-101.

18. Misra M and Lee MM. "Intersex disorders," in Moshang T., ed. Requisites in Pediatric Endocrinology. Philadelphia: W. B. Saunders 2005; 103-123.
19. Lee MM and Moshang T. "Endocrine Disorders of the Newborn" In Avery GB, Fletcher MA and MacDonald MG, eds. Avery's Neonatology: Pathophysiology and Management of the Newborn, 6th Edition. Philadelphia: Lippincott Williams & Wilkins 2005; 914-939.
20. Catlin EA and Lee MM. "Neonatal Endocrinology," in McMillan JA (Ed-in-chief), DeAngelis CD, Feigin RD, and Jones MD, Jr, eds. Oski's Pediatrics: Principles and Practice, 4th ed., Philadelphia: Lippincott, Williams & Wilkins 2006, 411-423.
21. Lee MM and Levitsky LL. "Adrenal Disorders," in Burg FD, Ingelfinger JR, Polin RA, and Gershon A, eds. Current Pediatric Therapy, 18th Ed. Philadelphia: Saunders Elsevier 2006, 972-980.
22. Lee MM. "Testicular development and descent" in Polin RA, Abman S, and Fox W, eds. Fetal and Neonatal Physiology, 4th ed. Philadelphia: Elsevier Saunders 2011, 2031-2038.
23. Wu XF, Zhang NN, and Lee MM. "The influence of endocrine disrupting compounds on male pubertal development," Diamanti-Kandarakis E and Gore A, eds. Endocrine Disruptors and Puberty, New York: Springer 2011, 339-356.
24. Lee MM. "Endocrine disruptors and puberty," in Preedy VR, ed. The Handbook of Growth and Growth Monitoring in Health and Disease, New York: Springer, 2012, 2773-2787.
25. Feldman P and Lee MM. "Endocrine Disorders of the Newborn" In MacDonald MG and Seshia MMK eds, Avery's Neonatology: Pathophysiology and Management of the Newborn, 7th Edition. Philadelphia: Lippincott Williams & Wilkins 2016, 699-718.
26. Lee MM. "Testicular development and descent" in Polin RA, Abman S, and Fox W, eds. Fetal and Neonatal Physiology, 5th Ed. Philadelphia: Elsevier Saunders 2016, 2031-2038.
27. Feldman P and Lee MM. "Idiopathic and normal variant short stature," in Radovick S and Misra M, eds. Pediatric Endocrinology: A Practical Clinical Guide 3rd ed. 2018, pp.

Presentations:

Invited Talks at National or International Meetings

- 5/7/2018 *Pediatric Endocrinology: an environmental perspective*, PES Presidential Lecture, Pediatric Academic Societies 2018 Annual Meeting, Toronto, Canada
- 3/9/2017 *Effects of Endocrine Disruptors and Environmental Chemicals on Puberty*, 9th International Pediatric Endocrine Meeting, Washington, DC (Symposium)
- 7/2015 *Environmental Influences on Pubertal Timing*, American Society of Teratology, Montreal, CA (Plenary session)
- 10/2013 *Endocrine Disruptors: What are the Effects in the Home - What Pediatricians Should look for*, AAP National Conference and Exhibition, Orlando, FL (Symposium)
- 10/2013 *Endocrine Disruptors: Longitudinal Cohort Studies in Highly Exposed Boys*. AAP National Conference and Exhibition, Orlando, FL (Plenary session)
- 5/2012 *EDCs and reproductive health*, Pediatric Academic Societies 2012 Annual Meeting, Boston, MA (Plenary session).
- 4/2012 *Endocrine disruptors*, Pediatric Endocrine Society: Update in Pediatric Endocrinology, Boston, MA.
- 9/2010 *Chapaevsk Boys Study: Effect of Dioxins on Growth and Puberty*, 100th Anniversary Celebration of the Chapaevsk Medical Association, Chapaevsk, Russia
- 5/2010 *Effects of endocrine disruptors on reproductive development*, Pediatric Academic Societies 2010 Annual Meeting, Vancouver, CA (Plenary session)
- 4/2010 *Normal and abnormal pubertal development*, American Society of Andrology 35th Annual Meeting, Houston, TX (Plenary session)
- 5/2007 *Endocrine Disruptors*, A Current Review of Pediatric Endocrinology, BioSymposia, Toronto, Canada.

- 3/2003 *Clinical and basic Insights on the role of Mullerian inhibiting substance in sexual differentiation and gonadal development*, Women in Andrology Plenary Lecture, American Society of Andrology 29th Annual Meeting, Phoenix, AZ.
- 10/2002 *AMH/MIS for the assessment of testicular status*, First International Workshop on AMH/MIS, Sero Symposium, Aix-en-Provence, France.
- 5/2000 *Mullerian inhibiting substance: Classical applications for a nonclassical hormone*, Pediatric Endocrinology at the Millennium, Sero Symposium, Boston, MA.
- 4/1999 *MIS actions in the developing testis*, XVth North American Testis Workshop: from Stem Cell to Sperm Function, Louisville, Ky.
- 10/1997 *Mullerian inhibiting substance: a new test for the evaluation of gonadal disorders*, Seminars in Pediatric Endocrinology, National University of Athens, Athens, Greece.

Other Invited Talks and Grand Rounds

- 10/2015 *Puberty in the 21st Century: What is causing shifts in timing?* Pediatric Grand Rounds, Morristown Medical Center, Morristown, NJ
- 10/2015 *Puberty in the 21st Century: What is causing shifts in timing?* Pediatric Grand Rounds, Overlook Medical Center, Summit, NJ
- 11/2012 *Chapaeusk Boys Study: association of environmental exposures with growth, puberty, and metabolic health*, Endocrine Grand Rounds, University of Indiana School of Medicine, Indianapolis, IN.
- 11/2012 *Endocrine disrupting compounds: the Good, the Bad, and the Ugly*, Pediatric Grand Rounds, Riley Children's Hospital, Indianapolis, IN.
- 3/2012 *Endocrine disruptors, reproductive and metabolic health*, University of Massachusetts Pediatric Grand Rounds, Worcester, MA
- 2/2012 *Environmental endocrine disruptors and the shifting tempo of puberty*, Duke University Medical Center, Durham, NC.
- 10/2011 *Endocrine disrupting compounds, growth, and pubertal development*, Dartmouth Pediatric Endocrine Annual meeting, Manchester, NH.
- 06/2011 *Dioxins and male reproductive health*, University of Massachusetts Pediatric Grand Rounds, Worcester, MA
- 6/2010 *ABCs of Diabetes Management in the Community*, UMassMemorial School Nurses Annual Update Program, Pediatric Diabetes Day, UMassMemorial, Worcester, MA
- 9/2007 *Dioxins and Male Reproductive Development*, Children's Hospital of Philadelphia, Philadelphia, PA
- 12/2009 *Dioxin effects on growth and puberty*, Helen Jones Memorial Lecture, MassGeneral Hospital for Children, Massachusetts General Hospital, Boston, MA
- 5/2007 *Endocrine Disruptors*, Sero Symposium on Pediatric Endocrinology, Montreal, CA
- 5/2006 *Mullerian inhibiting substance: emerging roles in the testis and clinical insights*, Endocrine Grand Rounds, Children's Hospital of Boston, Boston, MA
- 4/2006 *Mullerian inhibiting substance: clinical insights and emerging postnatal roles*, Endocrine Grand Rounds, University of Louisville, KY
- 1/2006 *Puberty: too early, too late?*, Health Alliance Pediatric Grand Rounds, Leominster, MA
- 10/2005 *MIS in Reproductive Disorders: from Bench to Bedside*, Endocrine Grand Rounds, Rhode Island Hospital, Brown University Medical School, Providence, RI
- 5/2005 *Novel roles for MIS/AMH in the postnatal reproductive system*, Patricia K. Donahoe Research Symposium, Massachusetts General Hospital, Boston, MA
- 3/2005 *Disorders of Puberty*, UMass Community Pediatric Updates," Jiminy Peak, MA
- 1/2005 *Congenital Adrenal Hyperplasia: Challenges in Management*, Pediatric Grand Rounds, University of Massachusetts Medical Center, Worcester, MA
- 12/2004 *MIS: a critical modulator of testicular Leydig cells*, Endocrine Grand Rounds, University of Massachusetts Medical Center, Worcester, MA

- 2/2004 *Modulation of Leydig cell differentiation by Mullerian inhibiting substance*, Research Seminar, NIEHS, Research Triangle Park, NC.
- 11/2003 *Clinical and basic insights on Mullerian inhibiting substance*, Endocrine Grand Rounds, Duke University Medical Center, Durham, NC.
- 11/2003 *Evaluation of Intersex Disorders*, Pediatric Conference, University of Massachusetts Medical Center, Worcester, MA
- 11/2003 *Dioxins and male reproductive health*, Pediatric Grand Rounds, MassGeneral Hospital for Children, Boston, MA.
- 10/2003 *Impact of maturational stage on the actions of 2,3,7,8 TCDD in testicular Leydig cells*, Duke Integrated Toxicology Program Seminar Series, Duke University Medical Center, Durham, NC.
- 4/2003 *Hair today, gone tomorrow*, Pediatric Grand Rounds, Duke University Medical Center, Durham, NC.
- 11/2002 *MIS/AMH in the evaluation of gonadal disorders*, 2002 Southern Pediatric Endocrine Society Annual Meeting, Columbia, SC.
- 5/2002 *Mullerian inhibiting substance in clinical medicine: facts and fantasies*, Delaware Valley Pediatric Endocrine Group and Children's Hospital of Philadelphia, Philadelphia, PA
- 2/2002 *The Paracrine Role of MIS in Leydig cell development*, Triangle Consortium for Reproductive Biology Annual Meeting, Research Triangle Park, NC
- 9/2000 *Mullerian inhibiting substance: from bench to bedside*, Joint UNC/Duke Endocrine Conference, Chapel Hill, NC
- 2/2000 *Regulation of Leydig cell maturation by MIS*, Reproductive Endocrine Sciences P30 Lecture Series, Boston, MA
- 11/1999 *Update on Management of the Infant with Genital Ambiguity*, Pediatric Grand Rounds, MassGeneral Hospital for Children, Boston, MA
- 3/1999 *Evaluation of intersex disorders*, Annual New England Pediatric Endocrine Nursing Society Meeting, Boston, NY
- 3/1998 *Developmental Regulation of Leydig cells by Mullerian inhibiting substance*, Endocrinology and Reproductive Biology Seminar Series, Population Council (Rockefeller University), New York, NY
- 2/1998 *Mullerian inhibiting substance regulation of testicular development*, Endocrine Research Conference, Children's Hospital of Philadelphia, Philadelphia, PA
- 2/1997 *Mullerian inhibiting substance: Clinical relevance to Pediatric Endocrinology*, Endocrine Grand Rounds, Children's Hospital of Boston, Boston, MA
- 2/1997 *Precocious Puberty*, East Boston Health Center, East Boston, MA
- 3/1996 *Evaluation and management of intersex disorders*, Pediatric and OB/GYN Joint Grand Rounds, Beth Israel Hospital, New York, NY
- 1/1996 *Basic and clinical studies of Mullerian Inhibiting Substance*, Research seminar, Children's Hospital of Philadelphia, Philadelphia, PA
- 5/1995 *MIS in gonadal physiology*, Endocrine Grand Rounds, Massachusetts General Hospital, Boston, MA
- 11/1993 *Update on Congenital Adrenal Hyperplasia*, Pediatric Grand Rounds, Massachusetts General Hospital, Boston, MA
- 11/1987 *Short stature*, Perspectives on Growth and Obesity in the Adolescent, Delaware Valley Adolescent Medicine Society Symposium, Philadelphia, PA

Committee Assignments and Administrative Service:

Grant Review Committees

External Advisory Committee:	2016-present
Developmental Impact on NICU Exposures (DINE)" Study	
Marsden Fund Council / Royal Society of New Zealand	2010-2013
Member, National Advisory Scientific Council, NIEHS	2010-2013

Charles Hood Medical Foundation, Grant Review Board	2009-2013
Chair	2012-2013
NIEHS Children's Environmental Health Centers Review Panel (ad hoc)	2009
NICHD, Gynecology, Reproduction and Andrology Study Section	2004-2008
Study Section Chair	2006-2008
Charles Hood Medical Foundation, Ad Hoc Reviewer	2004
NICHD, Reproductive Biology RFA Review Panel	2003
VA Merit Grant Review Board	2001
NICHD, Reproductive Biology, Program Project Review	1999-2002

Academic Committees/Service:

Nemours Al duPont Hospital for Children	
Medical Staff Executive Committee	2018-current
Delaware Valley Leadership Team	2018-current
EBright Development Committee	2018-current
DE Health Sciences Alliance	2018-current
Meyers Primary Care Institute Board of Directors	2013-2018
Massachusetts Child Health Quality Coalition (CHQC)	2013-2018
NIEHS and NCI	
Breast Center and the Environment Research Programs	2010-2014
External Advisory Board Member	
Ad Hoc Reviewer, Board of Scientific Counselors, NIEHS	2017
UMass Medical School/UMass Memorial Health Care:	
Executive Council Workgroup: Under-Represented Minorities (URM)	2016
Advisory Committee for the Opioid Conscious Curriculum (Medical School)	2016
Growth Committee	2015-2018
Transplant Quality Council Steering Committee	2013-2018
Nominations Committee (Medical School)	2014
Reviewer Selection Committee for Departmental Reviews	2014-2017
Medical Group Senior Management Team	2012-2018
Finance Committee	2014-2018
Executive Leadership Council (Medical School)	2012-2018
Clinical Chairs Council	2012-2018
Medical Staff Executive Committee	2012-2018
Women's Leadership Workgroup	2012-2018
UMCCTS CC-CHOC Pediatric point person	2012-2018
Re-accreditation by CIHE/NEASC	2011-2012
Subcommittee on standards for accreditation	
LCGME Task Force (Subcommittee on Personnel Policy)	2010-2011
Tenure Committee	2009-2012
Search Committees	
UMMS Executive Director for Advancement	2016-2017
Neonatology Division Search	2015-2016
UMMS Vice Chancellor for Development	2015
UMMHC COO	2014-2015
Shriver Institute Director	2014-2015
Pediatric GI Chief (Co-chair)	2010-2011

Diabetes Center of Excellence Research Faculty	2010-2011
Ob/GYN senior research faculty	2009-2010
Stem Cell Center Director	2008-2010
Diabetes Division Chief	2008-2009
Diabetes Center Director	2007-2008
Dean of Nursing	2005-2006
Faculty Advancement Departmental Liaison	2008-2016
National Children's Health Study, Scientific Advisory Board	2008-2015
UMCCTS Scientific Review Committee	2008-2018
Women's Faculty Committee	2008-2017
Pediatric Strategic Planning Task Force	2007
Chair, Academic Excellence Task Force	
Diabetes and Endocrine Research Center, Executive Committee	2007-2018
Diabetes Center for Excellence, Advisory Board	2007-2008
Faculty and Leadership Development Task Force	2007-2008
Departmental Policy and Action Committee	2005-2009
Scientific Academic Council	2004-2007
Duke University Medical Center	
Pediatric interest group (PIG)	2004
Annual research symposium organizing committee	2003-2004
Organizer, Ped Endocrine didactic conferences and journal clubs	2000-2004
Massachusetts General Hospital:	
Pediatric Safety Committee	1998-2000
Pediatric Academic Council	1999-2000
Subcommittee on the Review of Research Proposals	1994-1997
Children's Hospital of Philadelphia:	
Fellowship Review Committee	1986-1989

Civic and Community Activities:

Clara Barton Center for Diabetes Education:	
Medical Advisory Council	2005-2018
Trustee, Board of Trustees	2006-2018
Medical Director and Camp doctor	2005-2009
Worcester Half Marathon, health care team volunteer	2010
Special Olympics, volunteer	2008, 2009